SOTIO makes several additions to advisory board

The company has hired three clinical oncology research experts and biotechnology business development and commercialisation professionals

SOTIO Biotech, a clinical stage immune-oncology company owned by PPF Group, has announced the addition of three clinical oncology research experts and biotechnology business development and commercialisation professionals to its strategic advisory board. The additions include Alise Reicin, Josep Tabernero, and Anthony Tolcher.

“With the newest additions to our strategic advisory board, SOTIO and its stakeholders can continue advancing superior oncology research, drug and business development strategy with the highest caliber of guidance and expertise,” said Radek Spisek, CEO of SOTIO. “Doctors Reicin, Tabernero and Tolcher are internationally-recognised for their accomplishments in our field and bring to SOTIO some of the finest track records as both physicians and industry experts. We look forward with excitement to their future contributions to the achievement of SOTIO’s strategic corporate and clinical objectives, including the continued clinical advancement of our next generation cancer therapies and execution of future strategic partnerships.”

Reicin is CEO of Tectonic Therapeutic. She was most recently President, Global Clinical Development for Celgene where she oversaw the development and approval of drugs across their pipeline in Oncology, Hematology and Autoimmune diseases and Fibrosis. She currently serves on the board of directors of Homology Medicines, Sana Biotherapeutics and Sharsheret. Reicin has extensive early and late clinical development experience working across therapeutic areas.

Tabernero is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at University of Vic - Central University of Catalonia (UVic-UCC). He has been Principal Investigator of several Phase 1 pharmacodynamic studies and translational projects with tumor-directed targeted therapies and immune-based therapies.

Tolcher is CEO and founder of NEXT Oncology, San Antonio, Texas, a Phase I group that seeks to transform early clinical trials. Previously he served as President and co‐founder of START LLC from 2008‐2018, locations in San Antonio Texas; Grand Rapids, Michigan; Madrid Spain; and Shanghai China. Tolcher is a medical oncologist who has over 25 years’ experience in early drug development and clinical trials. He has been involved in more than 21 of the initial Phase I studies of new agents that subsequently were FDA approved for the treatment of cancer.